Polycyclo Ring System Patents (Class 514/185)
  • Patent number: 11395816
    Abstract: Disclosed is a family of corroles for its use in the treatment of an infection by human herpesvirus, especially in the treatment of an infection by human cytomegalovirus.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: July 26, 2022
    Assignee: UNIVERSITE DE BOURGOGNE
    Inventors: Claude Gros, Franck Gallardo, Nicolas Desbois
  • Patent number: 11389459
    Abstract: The present disclosure relates platinum(IV) and texaphyrin linked conjugates and compositions comprising a texaphyrin and a platinum(IV) agent. The present disclosure also provides pharmaceutical compositions of the conjugates and compositions. Also, provided herein are methods of using the instant compounds in the treatment of cancer such as a platinum resistant cancer.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: July 19, 2022
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jonathan L. Sessler, Jonathan Arambula, Zahid H. Siddik, Gregory Thiabaud
  • Patent number: 11382895
    Abstract: Compounds may be administered to prevent or rescue organ injury following exposure to alkylating agents, such as sulfur mustards. The compounds may be substituted metalloporphyrins.
    Type: Grant
    Filed: May 26, 2009
    Date of Patent: July 12, 2022
    Assignee: National Jewish Health
    Inventors: Brian J. Day, Carl W. White
  • Patent number: 11352658
    Abstract: The present invention relates to a method for selecting a target region of interest (ROI) in a target nucleic acid molecule using a nucleic acid probe comprising a 3? sequence capable of hybridising to a target nucleic acid molecule and acting as a primer for the production of a complement of the target ROI (i.e. by target templated extension of the primer), and a sequence capable of templating the circularisation and ligation of the extended probe comprising the reverse complement of the target ROI and a portion of the probe. The circularised molecule thus obtained contains the reverse complement of the target ROI and may be subjected to further analysis and/or amplification etc. The probe may be provided as an oligonucleotide comprising a stem-loop structure or as a partially double-stranded construct and comprises a single-stranded 3? end region containing the target-binding site.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: June 7, 2022
    Assignee: NAVINCI DIAGNOSTICS AB
    Inventors: Ulf Landegren, Rachel Yuan Nong
  • Patent number: 11298364
    Abstract: The present disclosure relates to methods and products for reducing the viability of microorganisms, and to methods and products for preventing and/or treating microorganism infections. Certain embodiments of the present disclosure provide a method for reducing viability of a microorganism. The method comprises exposing the microorganism to an effective amount of an iron chelator and subsequently exposing the microorganism to an effective amount of a non-iron porphyrin, thereby reducing the viability of the microorganism.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: April 12, 2022
    Assignee: The University of Adelaide
    Inventors: Sarah Vreugde, Peter John Wormald
  • Patent number: 11214826
    Abstract: The invention provides a method of karyotyping (for example for the detection of trisomy) a target cell to detect chromosomal imbalance therein, the method comprising: (a) interrogating closely adjacent biallelic SNPs across the chromosome of the target cell (b) comparing the result at (a) with the SNP haplotype of paternal and maternal chromosomes to assemble a notional haplotype of target cell chromosomes of paternal origin and of maternal origin (c) assessing the notional SNP haplotype of target cell chromosomes of paternal origin and of maternal origin to detect aneuploidy of the chromosome in the target cell. Also provided are related computer-implemented embodiments and systems.
    Type: Grant
    Filed: November 13, 2006
    Date of Patent: January 4, 2022
    Inventor: Alan Handyside
  • Patent number: 11135303
    Abstract: A conjugate of formula (A): where Y is selected from a single bond, and a group of formulae A1 or A2: where N shows where the group binds to the N10 of the PBD moiety; RL1 and RL2 are independently selected from H and methyl, or together with the carbon atom to which they are bound form a cyclopropylene group; CBA represents a cell binding agent; Q is independently selected from O, S and NH; R11 is either H, or R or, where Q is O, SO3M, where M is a metal cation.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: October 5, 2021
    Assignee: Medimmune Limited
    Inventors: John A. Flygare, Janet L. Gunzner-Toste, Thomas Pillow, Philip Wilson Howard, Luke Masterson
  • Patent number: 11104936
    Abstract: The present disclosure describes the thermodynamic design and concentrations necessary to design probe compositions with desired optimal specificity that enable enrichment, detection, quantitation, purification, imaging, and amplification of rare-allele-bearing species of nucleic acids (prevalence <1%) in a large stoichiometric excess of a dominant-allele-bearing species (wildtype). Being an enzyme-free and homogeneous nucleic acid enrichment composition, this technology is broadly compatible with nearly all nucleic acid-based biotechnology, including plate reader and fluorimeter readout of nucleic acids, microarrays, PCR and other enzymatic amplification reactions, fluorescence barcoding, nanoparticle-based purification and quantitation, and in situ hybridization imaging technologies.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: August 31, 2021
    Assignee: William Marsh Rice University
    Inventors: David Yu Zhang, Juexiao Wang
  • Patent number: 11078220
    Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: August 3, 2021
    Assignee: Mallinckrodt Hospital Products IP Limited
    Inventors: George S. Drummond, Robert Caroselli, Keith A. Cooke, Daniel Levin, David G. Roe, Christopher P. Boucher
  • Patent number: 11033753
    Abstract: A treatment method is disclosed capable of reducing the burden on a patient and enhancing the effect of killing tumor cells. A treatment method for killing a tumor cell, the method including inserting a catheter into a main artery of an organ having the tumor cell, administering an antibody-photosensitive substance into a vein before the inserting of the catheter, inserting an optical fiber into the catheter, reducing an influence of blood in the artery on a near-infrared ray, irradiating at least one of a tumor, the vicinity of the tumor, or a regional lymph node with a first near-infrared ray by the optical fiber, and irradiating an antibody-photosensitive substance bound to a tumor cell membrane in the tumor cell with a second near-infrared ray having a shorter wavelength than that of the first near-infrared ray.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: June 15, 2021
    Assignee: TERUMO KABUSHIKI KAISHA
    Inventors: Keiko Otsu, Yuji Onimura, Keiichiro Yamamoto, Takanobu Ishizuka
  • Patent number: 11034995
    Abstract: The present invention provides a method for detecting an analyte in a sample, said method comprising a) contacting said sample with a set of proximity probes comprising at least first and second proximity probes, which probes each comprise an analyte-binding domain capable of binding directly or indirectly to said analyte and a nucleic acid domain, such that the proximity probes can simultaneously bind, directly or indirectly, to the analyte, wherein i) the nucleic acid domains of said first and second proximity probes comprise regions capable of mediating an interaction involving said domains when under permissive conditions; and ii) the nucleic acid domain of one of said first and second probes comprises an HCR initiator region comprised within a metastable secondary structure such that it is unable to initiate an HCR reaction until released from said metastable secondary structure; b) introducing permissive conditions to allow the nucleic acid domains of said first and second probes to interact with each o
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: June 15, 2021
    Assignee: NAVINCI DIAGNOSTICS AB
    Inventors: Ola Söderberg, Björn Koos, Cosimo Ducani, Björn Högberg
  • Patent number: 10875871
    Abstract: The present application relates to a phthalocyanine, to a method for preparing the phthalocyanine, and to an object coated or impregnated with the phthalocyanine. The present application also relates to a method for providing reactive oxygen species, and to a method for disinfecting materials, including providing reactive oxygen species to the material to disinfect the material by oxidative action.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: December 29, 2020
    Assignee: Tampereen korkeakoulusäätiö sr
    Inventors: Alexander Efimov, George Lijo, Ville Santala
  • Patent number: 10786571
    Abstract: The present invention relates to a pharmaceutical topical gel solution that contains 5-aminolevulinic acid (5-ALA) and an aqueous low viscous gel matrix. This invention also relates to a pharmaceutical preparation containing this composition. The formulation of this type can be used in photodynamic therapy as well as in the photodynamic detection of abnormally proliferating cells.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: September 29, 2020
    Assignee: Zimmer Biotech GmbH
    Inventors: Andre Solioz, Frank Stowasser, Armin Zimmer
  • Patent number: 10759796
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: September 1, 2020
    Assignee: X4 PHARMACEUTICALS, INC.
    Inventors: Elyse Marie Josee Bourque, Renato Skerlj
  • Patent number: 10730899
    Abstract: The present disclosure is in relation to the field of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to platinum based compounds comprising platinum moiety, linker moiety and lipid moiety and corresponding nanoparticles thereof. The disclosure further relates to synthesis of said platinum based compounds, nanoparticles and compositions comprising said platinum based compounds/nanoparticles. The disclosure also relates to methods of managing cancer by employing aforesaid carbene compounds, platinum based compounds, nanoparticles and compositions thereof.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: August 4, 2020
    Assignee: AKAMARA THERAPEUTICS, INC.
    Inventors: Shiladitya Sengupta, Monideepa Roy, Arindam Sarkar, SK Samad Hossain, Aniruddha Sengupta, Pradip Dutta, Aasif Ansari
  • Patent number: 10695446
    Abstract: A compound and method for detecting hypoxic cells and tissue are provided. The compound includes a probe selected from the group consisting of a hypoxia sensitive 2-nitroimidazole containing fluorescence imaging probe, a hypoxia sensitive reversible ON-OFF fluorescence imaging probe, a hypoxia sensitive azo-based fluorescence imaging probe, and combinations thereof. The method includes contacting the cells or tissue with the probe of any one of claims 1-13 and detecting fluorescent intensity of the cell or tissue, wherein increased fluorescent intensity indicates that the cells or tissue is hypoxic. Also provided are a method of synthesizing the compound and a method for synthesizing a therapeutic agent including the compound.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: June 30, 2020
    Assignee: Vanderbilt University
    Inventors: Imam Uddin, Ashwath Jayagopal, Jashim Uddin, John S. Penn, Lawrence J. Marnett
  • Patent number: 10682327
    Abstract: A composition and method for supplementing food, nutrition, and diet systems with omega-6 to omega-3 balanced oils comprising a synergistic blend of at least two oils. The composition further comprises a synergistic blend of long chain omega-3 oil as a means to further increase the nutritional value. The composition provides an effective increase in therapeutic and pharmacological properties in nutrition and diet systems.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: June 16, 2020
    Assignee: Omega Foods, LLC
    Inventors: Michael H. Gurin, Andrew G. Konopacki
  • Patent number: 10668080
    Abstract: Use of (pyrophosphato)platinum(II) or (pyrophosphato)platinum(IV) complexes (“phosphaplatin compounds”), especially (R,R)-1,2-cyclohexanediamine-(dihydrogen pyrophosphato)platinum(II) (or “PT-112”), as therapeutic agents for treatment of bone and blood cancers, or cancers that metastasize to bones, and methods thereof, are disclosed.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: June 2, 2020
    Assignee: Phosplatin Therapeutics LLC
    Inventors: Matthew Price, Tyler Ames
  • Patent number: 10662209
    Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: May 26, 2020
    Assignee: Mallinckrodt Hospital Products IP Limited
    Inventors: George S. Drummond, Robert Caroselli, Keith A. Cooke, Daniel Levin, David G. Roe, Christopher P. Boucher
  • Patent number: 10597415
    Abstract: Aspects of the present disclosure relate to compounds which have enhanced oral bioavailability. A transition metal complex includes a transition metal coordinated by a macrocycle comprising the pentaaza 15-membered macrocyclic ring corresponding to Formula A and two axial ligands having the formula —OC(O)X1. each of the two axial ligands has the formula —OC(?O)X1 wherein each X1 is independently substituted or unsubstituted phenyl or —C(—X2)(—X3)(—X4); each X2 is independently substituted or unsubstituted phenyl, or substituted or unsubstituted alkyl; each X3 is independently hydrogen, hydroxyl, alkyl, amino, —X5C(?O)R13 where X5 is NH or O, and R13 is C1-C18 alkyl, substituted or unsubstituted aryl or C1-C18 aralkyl, or —OR14, where R14 is C1-C18 alkyl, substituted or unsubstituted aryl or C1-C18 aralkyl, or together with X4 is (?O); and each X4 is independently hydrogen or together with X3 is (?O).
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: March 24, 2020
    Assignee: GALERA LABS, LLC
    Inventors: Jeffery L. Keene, Otto F. Schall, Dennis P. Riley
  • Patent number: 10561698
    Abstract: A hand sanitizing composition and a method of manufacture, wherein the composition includes a solvent from about 78% to about 96% by weight sufficient to operate as a carrier and solvent. The composition includes tetrasodium EDTA and/or Sodium Citrate from about 0.01% to about 1% by weight to operate as a buffer, stabilizer and chelating agent. The composition includes a humectant selected from the group of humectants consisting of: Cetyl Alcohol, Ceteryl Alcohol, and Steryl Alchohol from about 1.5% to about 5.5% by weight to emulsify, thicken and lubricate. The composition includes an emollient from about 0.1% to about 3.2% by weight and an antioxidant vitamin from about 0.01% to about 1% by weight. The composition includes a soothing agent in a therapeutically significant amount and a conditioner.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: February 18, 2020
    Inventor: Roger Wilson
  • Patent number: 10537750
    Abstract: A radiation detection system and method for a neutron capture therapy system, which may increase the accuracy of neutron beam irradiation dose of the neutron capture therapy system and find out a fault position in time. The neutron capture therapy system includes a charged particle beam, a charged particle beam inlet allowing the charged particle beam to pass through, a neutron beam generating unit which may generate a neutron beam after a nuclear reaction occurs between the neutron beam generating unit and the charged particle beam, a beam shaping assembly for adjusting the flux and the quality of the neutron beam generated by the neutron beam generating unit, and a beam outlet adjacent to the beam shaping assembly, the radiation detection system includes a radiation detection device for real-time detection of ? rays instantly emitted under neutron beam irradiation.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: January 21, 2020
    Assignee: NEUBORON MEDTECH LTD.
    Inventors: Yuan-Hao Liu, Ming-Chen Hsiao
  • Patent number: 10500609
    Abstract: A process of providing an antibacterial coating to the surface of an article including the steps of applying a layer of an antibacterial precursor layer to the surface of an article to which an antibacterial coating is to be applied, wherein said antibacterial precursor layer is a precursor from which the coating is to be formed; and directing a neutral molecular hydrogen flux from a neutral molecular hydrogen flux emission source towards the surface of the article. Upon impact of neutral hydrogen molecules on molecules at or on the surface of an article, the bonds of the antibacterial precursor layer are selectively ruptured, and wherein the selectively ruptured bonds cross-link with themselves or with other chemical moieties at said surface or a combination thereof, resulting an antibacterial coating being formed on the surface of the article.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: December 10, 2019
    Assignee: MASTER DYNAMIC LIMITED
    Inventors: Yingnan Wang, Zhuonan Miao, Ching Tom Kong, Woon Ming Lau, Sui Kong Hark, Ka Wai Wong
  • Patent number: 10493081
    Abstract: The present disclosure relates to methods of treating a range of diseases or conditions. The methods involve administration of a superoxide dismutase mimetic.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: December 3, 2019
    Assignee: Galera Labs, LLC
    Inventors: Jeffery L. Keene, Dennis P. Riley, Robert A. Beardsley
  • Patent number: 10450322
    Abstract: The present invention relates to carboxamide halogenated porphyrin derivatives, in particular bacteriochlorin or chlorin, of formula (I) use of the same or a pharmaceutically acceptable salt thereof in photodynamic therapy, where the derivatives are able to detect and exhibit the presence of hyperproliferative disorders and, in the presence of an adequate lighting, to treat the same. The present invention also describes a pharmaceutical composition having the carboxamide halogenated porphyrin derivatives, in particular bacteria-chlorin or chlorin, of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of cancer and/or microbial and/or viral infections, in humans or animals.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: October 22, 2019
    Assignees: LUZITIN, S.A., UNIVERSIDADE DE COIMBRA
    Inventors: Goncalo Pereira Nascimento Costa, Nuno Paulo Ferreira Goncalves, Carlos Jorge Pereira Monteiro, Artur Carlos Reis De Abreu, Helder Tao Ferraz Cardoso Soares, Luis Gabriel Borges Rocha, Fabio Antonio Schaberle, Maria Miguens Pereira, Luis Guilherme Da Silva Arnaut Moreira
  • Patent number: 10406167
    Abstract: The present disclosure relates platinum(IV) and texaphyrin linked conjugates and compositions comprising a texaphyrin and a platinum(IV) agent. The present disclosure also provides pharmaceutical compositions of the conjugates and compositions. Also, provided herein are methods of using the instant compounds in the treatment of cancer such as a platinum resistant cancer.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: September 10, 2019
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jonathan L. Sessler, Jonathan Arambula, Zahid H. Siddik, Gregory Thiabaud
  • Patent number: 10358455
    Abstract: Disclosed is an arene ruthenium complex with R1, R2, R3, and piperidine as main ligands, preparation method and utilization thereof. R1, R2, R3 are selected from —H, —Cl, —F, —Br, —I, —CF3, —NO2, —OCH3, —OH, —COOH, —CH3, —N(CH3)2, —C2H2, —SO2CH3, alkane with 1 to 6 carbon atoms, substituted alkyl with 1 to 6 carbon atoms, phenyl, substituted phenyl, pyridyl, substituted pyridyl, furyl, substituted furyl, pyrrolyl, substituted pyrrolyl, thiazyl or substituted thiazyl group respectively. The substituted groups in the substituted phenyl, substituted pyridyl, substituted furyl, substituted thiazyl and substituted pyrrolyl are selected from hydroxyl, nitro, halogen, amido, carboxyl, cyano, thiol or naphthene group with 3 to 8 carbon atoms, SO3H, alkane with 1 to 6 carbon atoms, alkenyl with 2 to 6 carbon atoms, alkyne with 2 to 6 carbon atoms, C1-C6 hydroxyalkane, C1-C6 aminoalkane, CO2R?, CONR?R?, COR?, SO2R?R?, C1-C6 alkoxyl, C1-C6 alkyl thiol, —N?NR?, NR?R? or C1-C6 trifloroalkyl.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: July 23, 2019
    Assignee: GUANGDONG PHARMACEUTICAL UNIVERSITY
    Inventor: Wenjie Mei
  • Patent number: 10335608
    Abstract: A method for destroying cells and/or microorganisms in an organism includes the following steps: (a) administering to the organism a composition including a photodynamic compound containing at least one transition metal; and (b) irradiating the photodynamic compound in the organism with electromagnetic radiation, wherein the electromagnetic radiation includes ionizing radiation and is effective to activate the photodynamic compound to destroy at least one of the cells and the microorganisms in the organism. The ionizing radiation is preferably X-rays and/or gamma rays. The non-ionizing radiation is preferably light in the range from 600-950 nm.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: July 2, 2019
    Assignees: THERALASE TECHNOLOGIES, INC., UNIVERSITY HEALTH NETWORK
    Inventors: Arkady Mandel, Carl Fisher, Lothar Lilge
  • Patent number: 10328085
    Abstract: The use of cobalt porphyrins for the manufacture of an agent for mobilizing bone marrow cells to peripheral blood, preferably used to treat congenital neutropenia, for the treatment and prevention of neutropenia caused by chemotherapy, radiotherapy and pharmacologically-induced neutropenia, for the treatment of acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndromes, and to increase the amount of circulating hematopoietic stem cells in peripheral blood for subsequent isolation in the process of apheresis and allogeneic or autologous transplantation.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: June 25, 2019
    Assignee: UNIWERSYTET JAGIELLONSKI
    Inventors: Agata Szade, Krzysztof Szade, Alicja Jozkowicz, Jozef Dulak
  • Patent number: 10166222
    Abstract: This invention is directed to derivatives of piperidine-2,6-dione, or their organic or inorganic salts thereof, a methods of synthesis of these derivatives, and their application as active pharmaceutical ingridient as inhibitors of TNF? releasing in cells, the derivative of piperidine-2,6-dione being of the general formula (I): wherein n represents 1, 2, 3, 4, 5 or 6; R1 represents from one to four of the same or different substituents selected from F, Cl, Br, C1-4 alkyl, OH, OC1-4 alkyl, NO2, NHC(O)C1-4 alkyl, NH2, NH(C1-4 alkyl), N(C1-4 alkyl)2; R2 represents OR3, NR3R4, N(R3)COR4, O2CR5; R3 and R4 represent independently and at each occurrence H or C1-4 alkyl; R5 represents CHR6NR7R8, CHR6NR9C(O)CHR10NR7R8, a heterocycle W or CHR6NR9C(O)W; R6, R9, R10 represent independently and at each occurrence H, or C1-4 alkyl; R7 and R8 represent independently and at each occurrence H, C1-4 alkyl, or R7 and R8 taken together represent 1,3-propylene, 1,4-butylene, 1,5-pentylene , or 1,6-hexylene; W represents four-
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: January 1, 2019
    Assignee: Tianjin Hemay Bio-Tech Co., Ltd.
    Inventor: Hesheng Zhang
  • Patent number: 10111842
    Abstract: Provided herein are photosensitizer compounds for use in a variety of clinical, industrial, and research applications. In particular, provided are deep eutectic solvents and natural deep eutectic solvents for use in killing of bacteria.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: October 30, 2018
    Assignee: University of Oslo
    Inventors: Hanne Hjorth Tønnesen, Kristine Opsvik Wikene
  • Patent number: 10080759
    Abstract: A method of treating pruritus (itching) in a subject in need thereof is carried out by administering the subject an active agent in a treatment effective amount, wherein the active agent is a superoxide dismuate (SOD) mimetic. The SOD mimetic can be a complex of a metal (e.g., manganese) and an organic ligand, with suitable organic ligands including porphyrins, polyamines, salens, nitroxides, and fullerenes. Compositions for carrying out such methods are also described.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: September 25, 2018
    Assignees: Duke University, BioMimetix J.V., LLC
    Inventors: Ru-Rong Ji, Tong Liu, Ines Batinic-Haberle, David S. Warner, Kimberly C. Stone, James D. Crapo
  • Patent number: 10010557
    Abstract: The use of cobalt porphyrins for the manufacture of an agent for mobilizing bone marrow cells to peripheral blood, preferably used to treat congenital neutropenia, for the treatment and prevention of neutropenia caused by chemotherapy, radiotherapy and pharmacologically-induced neutropenia, for the treatment of acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndromes, and to increase the amount of circulating hematopoietic stem cells in peripheral blood for subsequent isolation in the process of apheresis and allogeneic or autologous transplantation.
    Type: Grant
    Filed: May 9, 2015
    Date of Patent: July 3, 2018
    Assignee: UNIWERSYTET JAGIELLONSKI
    Inventors: Agata Szade, Krzysztof Szade, Alicja Jozkowicz, Jozef Dulak
  • Patent number: 9969858
    Abstract: A composition including a metalloinsertor conjugate that specifically targets mismatch repair (MMR)-deficient cells includes a complex represented by Formula I. Mm+(L1)(L2)(L3)(L4)(L5)??Formula I Selective cytotoxicity may be induced in MMR-deficient cells upon uptake of the metalloinsertor conjugate. Metalloinsertor complexes conjugated with platinum (Pt) may allow for more specific targeting of platinum anticancer agents.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: May 15, 2018
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Alyson Weidmann, Jacqueline K. Barton
  • Patent number: 9969759
    Abstract: Disclosed herein are organometallic complexes and methods of using the same in detecting double stranded DNA or RNA, selectively over single stranded DNA or RNA.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: May 15, 2018
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Chad A. Mirkin, Chad M. Shade, Robert D. Kennedy, Jessica Lynn Rouge, Soyoung E. Seo, Mary X. Wang
  • Patent number: 9867391
    Abstract: The present invention generally relates to the field of medical nutrition. For example, the present invention provides a composition that can be used to treat, prevent and/or reverse muscle atrophy related to immobilization and its consequences. One embodiment of the present invention concerns a composition comprising a leucine and antioxidants that can be used in accelerating muscle recovery after muscle atrophy.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: January 16, 2018
    Assignee: Nestec S.A.
    Inventors: Dominique Dardevet, Isabelle Savary-Auzeloux, Didier Remond, Lydie Combaret, Gary Williamson, Magali Faure, Denis Breuille
  • Patent number: 9855279
    Abstract: Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: January 2, 2018
    Assignee: GALERA LABS, LLC
    Inventors: David M. Rothstein, Chris Murphy, Vivien Wong, Glenn Kazo
  • Patent number: 9765103
    Abstract: The present invention relates to using a versatile synthetic approach to generate a new class of ester, amido, or carbamate prodrugs of highly potent, but systemically too toxic, platinum-acridine anticancer agents. The new hybrids contain a hydroxyl group, which has been masked with a cleavable lipophilic acyl moiety. Both butanoic (butyric) and bulkier 2-propanepentanoic (valproic) esters were introduced to these compounds. The goal of this design was to improve the drug-like properties of the pharmacophore (e. g., log D) without compromising its DNA-mediated cell kill potential. Two distinct pathways by which the target compounds undergo effective ester hydrolysis, the proposed activating step, have been confirmed: platinum-mediated, self-immolative ester cleavage in a low-chloride environment (LC-ESMS, NMR spectroscopy) and enzymatic cleavage by human carboxylesterase-2 (hCES-2) (LC-ESMS).
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: September 19, 2017
    Inventors: Ulrich Bierbach, Song Ding
  • Patent number: 9603928
    Abstract: The object of the present invention is to elucidate the resistance mechanism in infections that show resistance to ALA-PDT that uses a single ALA, and to provide a novel treatment method against these infections. The present invention provides a pharmaceutical composition for promoting protoporphyrin IX production in ALA-PDT for treating infection, characterized in that it comprises a substance that promotes the conversion from coproporphyrinogen III to protoporphyrin IX.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: March 28, 2017
    Assignees: SBI Pharmaceuticals Co., Ltd., Osaka City University
    Inventors: Masahiro Ishizuka, Urara Oto, Atsuko Kamiya, Kiwamu Takahashi, Tohru Tanaka, Toshiyuki Ozawa, Kuniyuki Morimoto, Keitaro Watanabe
  • Patent number: 9592219
    Abstract: A new self-magnetic metal-salen complex compound and its derivatives are provided. The present invention is a metal-salen complex compound including any one of the following compounds.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: March 14, 2017
    Assignees: IHI Corporation
    Inventors: Yoshihiro Ishikawa, Haruki Eguchi
  • Patent number: 9572795
    Abstract: This invention relates to photodynamic therapy (PDT) of vulnerable plaque using two pluralities of nanoparticles, one plurality comprising a PDT agent that is sensitive to blue-green light wherein the nanoparticles are capable of penetrating only into the fibrous cap of the vulnerable plaque and one plurality comprising a PDT agent that is sensitive to red light wherein the nanoparticles are capable of penetrating into the core of the vulnerable plaque.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: February 21, 2017
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventors: Syed Hossainy, Dariush Davalian, Mikael Trollsas, John Stankus, Jinping Wan
  • Patent number: 9555111
    Abstract: Wounds in the eye following surgery or injury are sealed by soaking the area with a riboflavin solution containing iodide ion and irradiating the wound area with UVA radiation in a selected wavelength range for a selected time period to promote cross-linking of tissue between opposite surfaces of the wound or between the incised wound surfaces and a graft or implant.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: January 31, 2017
    Assignee: CXL Ophthalmics, LLC
    Inventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
  • Patent number: 9517239
    Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: December 13, 2016
    Assignee: Infacare Pharmaceutical Corporation
    Inventors: George S. Drummond, Robert Caroselli, Keith A. Cooke, Daniel Levin, David G. Roe, Christopher P. Boucher
  • Patent number: 9480657
    Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum compound having a heterocycle ligand. Cabazitaxel-platinum nanoparticles are disclosed herein, as well as methods of making and using the same.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: November 1, 2016
    Assignee: Tarveda Therapeutics, Inc.
    Inventors: Mark T. Bilodeau, Craig A. Dunbar, Timothy E. Barder, Edward R. Lee, Rossitza G. Alargova, Danielle N. Rockwood
  • Patent number: 9365593
    Abstract: The present invention provides compounds of Formula I: along with compositions comprising the same and methods of using the same, such as for photodynamic therapy in the treatment of cancer.
    Type: Grant
    Filed: March 21, 2013
    Date of Patent: June 14, 2016
    Assignee: Duke University
    Inventors: Katherine J. Franz, Katie L. Ciesienski
  • Patent number: 9309247
    Abstract: The present invention provides 2-substituted imidazo[4,5-d]phenanthroline compounds, which are capable of inhibiting proliferation of one or more renal cancer cells, pancreatic cancer cells, prostate cancer cells, colon cancer cells, leukemia cells, brain cancer/tumor cells or non-small cell lung cancer cells.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: April 12, 2016
    Assignee: LORUS THERAPEUTICS INC.
    Inventors: Yoon Lee, Howard Cukier, Venkata Nedunuri, Robert Peralta, Mario Huesca, Aiping H. Young
  • Patent number: 9290528
    Abstract: The presently-disclosed subject matter includes light-activated ruthenium compounds. In some embodiments the compounds release one or more ligands when exposed to light, and in specific embodiments the light includes a wavelength of about 500 nm to about 1000 nm. The present compounds can also comprise an overall charge, wherein the overall charge can be a positive overall charge or a negative overall charge. Further still, embodiments include methods of treating cancer in a subject by administering a compound and then exposing a site of the subject to light.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: March 22, 2016
    Assignee: University of Kentucky Research Foundation
    Inventors: Edith C. Glazer, David K. Heidary
  • Patent number: 9289434
    Abstract: The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: March 22, 2016
    Assignees: Aeolus Sciences, Inc., National Jewish Health, Duke University
    Inventors: James D. Crapo, Brian J. Day, Michael P. Trova, Polivina Jolicia F. Gauuan, Douglas B. Kitchen, Irwin Fridovich, Ines Batinic-Haberle
  • Patent number: 9222922
    Abstract: A high performance liquid chromatography method to routinely and reproducibly detect and quantitate metal complexes is provided. The metal complexes used in the method of the invention can be different metal complexes, or they can be stereoisomers of the same metal complexes. The high performance liquid chromatography method of the present invention is suitable for the separation of diastereomers of the same metal complexes. Also provided is a chiral high performance liquid chromatography method to separate enantiomers of metal complexes. Superoxide dismutase mimetic compounds are also provided.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: December 29, 2015
    Assignee: Galera Labs, LLC
    Inventors: Urszula J. Slomczynska, Bobby N. Trawick, Dennis P. Riley, Arati Naik
  • Patent number: RE47123
    Abstract: Antagonistic antibodies that specifically bind to and inhibit Class A Eph receptors are provided. Also provided are cytotoxic conjugates, pharmaceutical compositions and kits comprising these antibodies.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: November 13, 2018
    Assignee: SANOFI
    Inventors: Veronique Blanc, Claudia Fromond, Fabienne Parker, Jiawen Han, Daniel Tavares, Chonghui Zhang, Min Li, Xiao-Mai Zhou, Michel Streuli